A reversed-phase ultrafast liquid chromatography method was developed for quantification of lansoprazole in pharmaceutical dosage form using analytical quality by design approach. Systematic planning and experimentation using design of experiment approach were used for method development and optimization studies. A central composite design was used for optimizing the chromatography, by choosing organic phase proportion and flow rate as the critical method variables for evaluating their effect on critical analytical attributes like resolution, plate number, and tailing factor. The optimal chromatography was accomplished on a C-18 column (250 × 4.6 mm, 5 µm) using methanol:water (70:30, v/v) as mobile phase at a flow rate of 1.0 mL/min. Photo diode array (PDA) detection was performed at 284 nm. Caffeine was used as the internal standard. Method validation studies revealed that the calibration curve was linear over 1.0–300 µg/mL. The method was found accurate with average recovery between 98.99 and 102.87%. The percent relative standard deviation values obtained for precision were as per ICH guideline and within the acceptance limits (<2%). Results of system suitability indicated superior method robustness. In a nutshell, the method was found to be highly suitable for its applicability in the determination of lansoprazole in bulk and tablet dosage form.
1 February 2015 in Journal of Chromatographic Science
Quality by design (QbD) approach thrives to achieve an assured and predicted quality product. A stability-indicating reversed phase ultrafast liquid chromatographic method was developed using the principles of QbD to quantify telaprevir (TEL) in pharmaceutical dosage form. A Box-Behnken experimental design was employed for identifying optimum chromatographic conditions by assessing the method robustness by selecting organic phase composition (%), mobile phase flow rate (mL/min) and pH of the borate buffer as the factors, to study their effect on the responses like retention time, theoretical plate count and tailing factor. Chromatographic separation was achieved on Enable-C18G (250 × 4.6 mm i.d., 5 µm) column using methanol: borate buffer of pH 9.0 (90 : 10, v/v) as mobile phase at a flow rate of 1.2 mL/min and PDA detection at 270 nm. Establishment of calibration curve yielded linearity in the range of 5–70 µg/mL along with values of accuracy and precision within the acceptance limit of mean percent recoveries between 98.9 and 100.7%. Limit of detection and limit of quantitation were found to be 1.60 and 4.75 µg/mL. Analysis of system suitability yielded high degree of method reproducibility and robustness. The developed method showed high specificity for TEL and its degradation products formed during forced degradation conditions. The developed method also demonstrated suitability for routine analysis of TEL in bulk drug and pharmaceutical dosage forms.
An ultra-fast liquid chromatographic method and two UV spectroscopic methods were developed for the determination of cephalexin monohydrate in pharmaceutical dosage forms. Isocratic separation was performed on an Enable C18G column (250 mm × 4.6 mm i.d., 5 μm) using methanol:0.01 M TBAHS (50:50, v/v) as the mobile phase at a flow rate of 1.0 ml/min. The PDA detection wavelength was set at 254 nm. The UV spectroscopic method was performed at 261 nm and at 256-266 nm for the AUC method using a phosphate buffer (pH=5.5). The linearity was observed over a concentration range of 1.0–120 μg/ml for UFLC and both of the UV spectroscopic methods (correlation coefficient=0.999). The developed methods were validated according to ICH guidelines. The relative standard deviation values for the intraday and interday precision studies were < 2%, and the accuracy was > 99% for all of the three methods. The developed methods were used successfully for the determination of cephalexin in dry syrup formulation.
A simple, precise and accurate isocratic RP-HPLC stability-indicating assay method has been developed to determine diclofenac potassium and metaxalone in their combined dosage forms. Isocratic separation was achieved on a Hibar-C(18), Lichrosphere-100(®) (250 mm × 4.6 mm i.d., particle size 5 μm) column at room temperature in isocratic mode, the mobile phase consists of methanol: water (80:20, v/v) at a flow rate of 1.0 ml/min, the injection volume was 20 μl and UV detection was carried out at 280nm. The drug was subjected to acid and alkali hydrolysis, oxidation, photolysis and heat as stress conditions. The method was validated for specificity, linearity, precision, accuracy, robustness and system suitability. The method was linear in the drug concentration range of 2.5-30 μg/ml and 20-240 μg/ml for diclofenac potassium and metaxalone, respectively. The precision (RSD) of six samples was 0.83 and 0.93% for repeatability, and the intermediate precision (RSD) among six-sample preparation was 1.63 and 0.49% for diclofenac potassium and metaxalone, respectively. The mean recoveries were between 100.99-102.58% and 99.97-100.01% for diclofenac potassium and metaxalone, respectively. The proposed method can be used successfully for routine analysis of the drug in bulk and combined pharmaceutical dosage forms.
Lack of quality analytical methods with assured robustness and reliability has always been a serious concern for drug regulatory agencies. In the present study, a contemporary approach of analytical life‐cycle management resulted in the robust and reliable chromatographic analysis of lacidipine at a retention time of 5.1 min on a C‐18 column. Method variables such as %acetonitrile, flow rate, and pH were optimized using the design of experiment approach and their effect on critical quality attributes was studied. The attributes of the present study were significantly influenced by %acetonitrile and flow of the mobile phase. The newly optimized method was validated for various parameters with values in accordance with federal guidance. The lifecycle approach proved to be beneficial for routine application with a potential of future bio‐analytical utility.